Compounded GLP-1 policy in 2026: what patients should verify

As checked October 22, 2026, FDA’s compounding policy page lists an April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk-substances list. A proposal is not a completed rule, and a bulk-list issue is not the same question as drug approval. FDA also has separate shortage and essentially-copy conditions. Ask the clinician and compounder what current provision supports the specific prescription; do not rely on an old social post. FDA: Human drug compounding policies and rules FDA: 503B bulk substances

FDA’s current unapproved GLP-1 page advises that compounded drugs be used only when a patient’s medical needs cannot be met by an approved drug and that patients obtain a prescription and use a state-licensed pharmacy. FDA says compounded drugs do not undergo its premarket safety, effectiveness, and quality review. This is a reason to ask why compounding is proposed in your case, not a blanket claim that every compounded medicine is illegal. FDA: Concerns with unapproved GLP-1 drugs FDA: Compounding and the FDA Q&A

FDA reports issues involving improper storage during shipping, confusing labels or instructions, dosing errors with multi-dose vials, and certain products represented as equivalent to approved medicines. It separately says retatrutide and cagrilintide cannot be used in compounding under federal law. These statements concern specific situations and substances; they do not turn all GLP-1 research into approved treatment. FDA: Concerns with unapproved GLP-1 drugs

Confirm the exact ingredient and form, prescriber, compounder, dispensing pharmacy, legal basis, total price, and follow-up contact. If an approved medicine can meet the need, ask why it is not being used. If the product changes between refills, request fresh instructions from the clinician or pharmacist. Check the date of the FDA guidance and ask how a policy change would affect your next prescription and continuity of care. FDA: Concerns with unapproved GLP-1 drugs FDA: Compounding during drug shortages

The April 2026 item concerns whether three named substances belong on the 503B bulk list. It does not mean FDA approved every brand-name product for every use, and it does not automatically resolve 503A, shortage, copy, or patient-specific questions. A service should explain the current basis for its own product without collapsing these separate rules into “legal” or “illegal” as a slogan. FDA: Human drug compounding policies and rules

Read the actual prescription and label, obtain the name of the compounder and dispensing pharmacy, and ask why an approved medicine cannot meet the medical need. If the shipment arrives warm or damaged, contact the pharmacy before use; FDA highlights shipping and labeling concerns in its current page. Keep the product and lot details for follow-up. These checks are concrete even while regulations continue to evolve. FDA: Concerns with unapproved GLP-1 drugs